Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) and Gossamer Bio (NASDAQ:GOSS – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.
Valuation and Earnings
This table compares Aclaris Therapeutics and Gossamer Bio”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aclaris Therapeutics | $8.22 million | 67.54 | -$64.92 million | ($0.58) | -6.84 |
| Gossamer Bio | $48.47 million | 1.31 | -$170.37 million | ($56.00) | -0.19 |
Aclaris Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Aclaris Therapeutics and Gossamer Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aclaris Therapeutics | 1 | 0 | 5 | 3 | 3.11 |
| Gossamer Bio | 2 | 3 | 5 | 0 | 2.30 |
Aclaris Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 177.08%. Gossamer Bio has a consensus target price of $256.00, indicating a potential upside of 2,366.28%. Given Gossamer Bio’s higher probable upside, analysts plainly believe Gossamer Bio is more favorable than Aclaris Therapeutics.
Risk & Volatility
Aclaris Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500.
Profitability
This table compares Aclaris Therapeutics and Gossamer Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aclaris Therapeutics | -921.50% | -61.65% | -42.41% |
| Gossamer Bio | -235.00% | N/A | -112.04% |
Institutional & Insider Ownership
98.3% of Aclaris Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 4.8% of Aclaris Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Aclaris Therapeutics beats Gossamer Bio on 8 of the 14 factors compared between the two stocks.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
